Michael Brown

Dr. Brown’s research focuses on leveraging intratumor innate immunity for cancer immunotherapy, particularly in the context of malignant brain tumors. Dr. Brown's lab uses mouse cancer models, ex vivo human tumor slice culture assays, and clinical trial associated specimens to decode mechanisms by which intratumor innate immune cells control cancer immune surveillance and develop novel in situ vaccine approaches that engage endogenous antitumor T cells. The Brown lab also collaborates with clinicians and other research groups to facilitate the translation of novel therapies, define determinants of successful immunotherapy, and elucidate mechanisms explaining immune dysfunction in patients with cancer.